Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-26T00:14:24.221Z Has data issue: false hasContentIssue false

Chemotherapy alone in laryngeal squamous cell carcinoma

Published online by Cambridge University Press:  28 September 2006

P Bonfils
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, European Hospital Georges Pompidou, Faculté de Médecine, Université Paris-Descartes, Paris, France
J Trotoux
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, European Hospital Georges Pompidou, Faculté de Médecine, Université Paris-Descartes, Paris, France
V Bassot
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, European Hospital Georges Pompidou, Faculté de Médecine, Université Paris-Descartes, Paris, France

Abstract

Aims: To evaluate the results of chemotherapy alone in patients with invasive squamous cell carcinoma of the larynx who have achieved a complete clinical response after an induction chemotherapy protocol.

Methods: A comparison of results in a group of complete responders managed with a chemotherapy alone protocol, matched with those of an incomplete responder group managed with conventional modalities.

Results: The survival rate of the complete responder group was significantly higher than that of the incomplete responder group. No statistically significant difference was noted between the two groups in terms of local failure and nodal recurrence.

Conclusion: Our results confirm the fact that chemotherapy alone is a viable option in selected patients with carcinoma of the larynx who have achieved a complete clinical response after an induction chemotherapy protocol. This therapeutic approach allows surgery and/or radiation therapy to be reserved for the management of metachronous second primary tumours.

Type
Main Articles
Copyright
2006 JLO (1984) Limited

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)